PURPOSE: Hemorrhage from an arteriovenous malformation (AVM) is the commonest cause of childhood stroke. Management options for children include observation and medical management, surgical resection, endovascular embolization, or stereotactic radiosurgery, alone or in combination. METHODS: Radiosurgery is used for high-risk malformations in critical brain locations. While this goal is being achieved, there should be limited morbidity and hopefully no mortality from hemorrhage or radiation-induced brain injury. RESULTS: Physicians who consider AVM radiosurgery cite one or more of the following: (1) that radiosurgery is an effective therapy required for the management of deep-brain AVMs; (2) that radiosurgery is an effective therapy for residual AVMs after subtotal resection; (3) that radiosurgery is worthwhile in an attempt to lower management risks for AVMs in functional brain locations; (4) since embolization does not cure most AVMs, additional therapy such as radiosurgery may be required; and (5) microsurgical resection may not be the best choice for some children. CONCLUSION: Radiosurgery is the first and only biologic AVM therapy; it represents the beginnings of future cellular approaches to vascular malformation diseases. For this reason, the future of radiosurgery may be impacted positively by the development of other biologic strategies such as brain protection or endothelial sensitization.
PURPOSE:Hemorrhage from an arteriovenous malformation (AVM) is the commonest cause of childhood stroke. Management options for children include observation and medical management, surgical resection, endovascular embolization, or stereotactic radiosurgery, alone or in combination. METHODS: Radiosurgery is used for high-risk malformations in critical brain locations. While this goal is being achieved, there should be limited morbidity and hopefully no mortality from hemorrhage or radiation-induced brain injury. RESULTS: Physicians who consider AVM radiosurgery cite one or more of the following: (1) that radiosurgery is an effective therapy required for the management of deep-brain AVMs; (2) that radiosurgery is an effective therapy for residual AVMs after subtotal resection; (3) that radiosurgery is worthwhile in an attempt to lower management risks for AVMs in functional brain locations; (4) since embolization does not cure most AVMs, additional therapy such as radiosurgery may be required; and (5) microsurgical resection may not be the best choice for some children. CONCLUSION: Radiosurgery is the first and only biologic AVM therapy; it represents the beginnings of future cellular approaches to vascular malformation diseases. For this reason, the future of radiosurgery may be impacted positively by the development of other biologic strategies such as brain protection or endothelial sensitization.
Authors: Sait Sirin; Douglas Kondziolka; Ajay Niranjan; John C Flickinger; Ann H Maitz; L Dade Lunsford Journal: Neurosurgery Date: 2006-01 Impact factor: 4.654
Authors: François Nataf; Michel Schlienger; Dimitri Lefkopoulos; Louis Merienne; May Ghossoub; Jean Noel Foulquier; Elisabeth Deniaud-Alexandre; Hamid Mammar; Jean-François Meder; Baris Turak; Judith Huart; Emmanuel Touboul; François-Xavier Roux Journal: Int J Radiat Oncol Biol Phys Date: 2003-09-01 Impact factor: 7.038
Authors: David Altschul; Srinivasan Paramasivam; Santiago Ortega-Gutierrez; Johanna T Fifi; Alejandro Berenstein Journal: Childs Nerv Syst Date: 2014-03-27 Impact factor: 1.475
Authors: Sunil A Sheth; Matthew B Potts; Penny K Sneed; William L Young; Daniel L Cooke; Nalin Gupta; Steven W Hetts Journal: Childs Nerv Syst Date: 2013-07-27 Impact factor: 1.475